A Phase 1b/2 Open-label Study of IMU-131 HER2/Neu Peptide Vaccine Plus Cisplatin and Either 5-Fluorouracil or Capecitabine Chemotherapy in Patients With HER2/Neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction

Trial Profile

A Phase 1b/2 Open-label Study of IMU-131 HER2/Neu Peptide Vaccine Plus Cisplatin and Either 5-Fluorouracil or Capecitabine Chemotherapy in Patients With HER2/Neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs IMU 131 (Primary) ; Capecitabine; Cisplatin; Fluorouracil
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions
  • Sponsors Imugene
  • Most Recent Events

    • 31 Aug 2017 According to an Imugene media release, the company has commenced first patient dosing this study. Patients are currently being enrolled at eight key cancer hospital sites in Asia, including Hong Kong, Thailand and Taiwan.
    • 19 Jul 2017 Planned primary completion date changed from 1 Mar 2018 to 1 May 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top